BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05275478 (TNG908 in MTAP-deleted Solid Tumors): BVCT ex-ante prediction vs. reported outcome

On 28 Jul 2024, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 6 Nov 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically maybe significant and commercially insufficient.

Clinical Trial

NCTID
NCT05275478
Drug Name
TNG908
Drug MoA
selective MTAP-mull-cell-specific PRMT5 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
MTAP-deleted Solid Tumors
Human Patients
192
Sponsor
Tango Therapeutics
Phase
Phase 1 Phase 2

Prediction of , index 1019

Prospective Prediction
Prediction Index
1019
Prediction Date
Commercial Prediction
partial SUCCESS (commercially maybe sufficient yet weak clinical benefit in OS)
Technical Prediction
SUCCESS (statistically significant clinical benefit in ORR/PFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
101 days in advance
Readout Data Interpretation
TNG908 exhibited overall weak efficacy (active for non-CNS solid tumors yet inactive for GBM)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically maybe significant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Phase
Phase 1, Phase 2
Status
Terminated
Enrollment
110
Lead sponsor
Tango Therapeutics, Inc.
Conditions
Locally Advanced Solid Tumor
Interventions
DRUG: TNG908
Design
Non randomized · Sequential · None
Primary purpose
Treatment
Start
2022-03-23
Primary completion
2025-12-30
Completion
2025-12-30
Primary outcomes
  • Phase 1: (28 days)
  • Phase 2: (16 weeks)

NCT05275478 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials